272 related articles for article (PubMed ID: 29866026)
1.
Pfannkuchen N; Bausbacher N; Pektor S; Miederer M; Rosch F
Curr Radiopharm; 2018; 11(3):223-230. PubMed ID: 29866026
[TBL] [Abstract][Full Text] [Related]
2.
Jiang Z; Revskaya E; Fisher DR; Dadachova E
Curr Radiopharm; 2018; 11(3):215-222. PubMed ID: 29683101
[TBL] [Abstract][Full Text] [Related]
3. Bone targeting compounds for radiotherapy and imaging: *Me(III)-DOTA conjugates of bisphosphonic acid, pamidronic acid and zoledronic acid.
Meckel M; Bergmann R; Miederer M; Roesch F
EJNMMI Radiopharm Chem; 2017; 1(1):14. PubMed ID: 29564390
[TBL] [Abstract][Full Text] [Related]
4. Preliminary results of biodistribution and dosimetric analysis of [
Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
[TBL] [Abstract][Full Text] [Related]
5. Development of
Robertson AKH; Ramogida CF; Schaffer P; Radchenko V
Curr Radiopharm; 2018; 11(3):156-172. PubMed ID: 29658444
[TBL] [Abstract][Full Text] [Related]
6. An Overview of Targeted Alpha Therapy with
Morgenstern A; Apostolidis C; Kratochwil C; Sathekge M; Krolicki L; Bruchertseifer F
Curr Radiopharm; 2018; 11(3):200-208. PubMed ID: 29732998
[TBL] [Abstract][Full Text] [Related]
7. Alpha radioimmunotherapy using
Cheal SM; McDevitt MR; Santich BH; Patel M; Yang G; Fung EK; Veach DR; Bell M; Ahad A; Vargas DB; Punzalan B; Pillarsetty NVK; Xu H; Guo HF; Monette S; Michel AO; Piersigilli A; Scheinberg DA; Ouerfelli O; Cheung NV; Larson SM
Theranostics; 2020; 10(25):11359-11375. PubMed ID: 33052220
[TBL] [Abstract][Full Text] [Related]
8. Bisphosphonates as Radiopharmaceuticals: Spotlight on the Development and Clinical Use of DOTAZOL in Diagnostics and Palliative Radionuclide Therapy.
Souche C; Fouillet J; Rubira L; Donzé C; Deshayes E; Fersing C
Int J Mol Sci; 2023 Dec; 25(1):. PubMed ID: 38203632
[TBL] [Abstract][Full Text] [Related]
9. Preclinical Evaluation of 225Ac-Labeled Single-Domain Antibody for the Treatment of HER2pos Cancer.
Rodak M; Dekempeneer Y; Wojewódzka M; Caveliers V; Covens P; Miller BW; Sevenois MB; Bruchertseifer F; Morgenstern A; Lahoutte T; D'Huyvetter M; Pruszyński M
Mol Cancer Ther; 2022 Dec; 21(12):1835-1845. PubMed ID: 36129807
[TBL] [Abstract][Full Text] [Related]
10. Clinical Studies with Bismuth-213 and Actinium-225 for Hematologic Malignancies.
Jurcic JG
Curr Radiopharm; 2018; 11(3):192-199. PubMed ID: 29793418
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of an Anti-HER2 Nanobody Labeled with
Pruszynski M; D'Huyvetter M; Bruchertseifer F; Morgenstern A; Lahoutte T
Mol Pharm; 2018 Apr; 15(4):1457-1466. PubMed ID: 29502411
[TBL] [Abstract][Full Text] [Related]
12. Development of CD46 targeted alpha theranostics in prostate cancer using
Bobba KN; Bidkar AP; Wadhwa A; Meher N; Drona S; Sorlin AM; Bidlingmaier S; Zhang L; Wilson DM; Chan E; Greenland NY; Aggarwal R; VanBrocklin HF; He J; Chou J; Seo Y; Liu B; Flavell RR
Theranostics; 2024; 14(4):1344-1360. PubMed ID: 38389832
[No Abstract] [Full Text] [Related]
13. Efficient 1-step radiolabeling of monoclonal antibodies to high specific activity with 225Ac for α-particle radioimmunotherapy of cancer.
Maguire WF; McDevitt MR; Smith-Jones PM; Scheinberg DA
J Nucl Med; 2014 Sep; 55(9):1492-8. PubMed ID: 24982438
[TBL] [Abstract][Full Text] [Related]
14. Efforts to control the errant products of a targeted in vivo generator.
Jaggi JS; Kappel BJ; McDevitt MR; Sgouros G; Flombaum CD; Cabassa C; Scheinberg DA
Cancer Res; 2005 Jun; 65(11):4888-95. PubMed ID: 15930310
[TBL] [Abstract][Full Text] [Related]
15. Carbonic Anhydrase IX-Targeted α-Radionuclide Therapy with 225Ac Inhibits Tumor Growth in a Renal Cell Carcinoma Model.
Merkx RIJ; Rijpkema M; Franssen GM; Kip A; Smeets B; Morgenstern A; Bruchertseifer F; Yan E; Wheatcroft MP; Oosterwijk E; Mulders PFA; Heskamp S
Pharmaceuticals (Basel); 2022 May; 15(5):. PubMed ID: 35631396
[TBL] [Abstract][Full Text] [Related]
16. (177)Lu-labelled macrocyclic bisphosphonates for targeting bone metastasis in cancer treatment.
Bergmann R; Meckel M; Kubíček V; Pietzsch J; Steinbach J; Hermann P; Rösch F
EJNMMI Res; 2016 Dec; 6(1):5. PubMed ID: 26780082
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics, dosimetry, and toxicity of the targetable atomic generator, 225Ac-HuM195, in nonhuman primates.
Miederer M; McDevitt MR; Sgouros G; Kramer K; Cheung NK; Scheinberg DA
J Nucl Med; 2004 Jan; 45(1):129-37. PubMed ID: 14734685
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of [
Cortez A; Josefsson A; McCarty G; Shtekler AE; Rao A; Austin Z; Nedrow JR
Nucl Med Biol; 2020; 88-89():62-72. PubMed ID: 32799049
[TBL] [Abstract][Full Text] [Related]
19. Detailed Chemistry Studies of
Eryilmaz K; Kilbas B
Curr Radiopharm; 2022; 15(1):76-83. PubMed ID: 34053430
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic efficacy and toxicity of 225Ac-labelled vs. 213Bi-labelled tumour-homing peptides in a preclinical mouse model of peritoneal carcinomatosis.
Essler M; Gärtner FC; Neff F; Blechert B; Senekowitsch-Schmidtke R; Bruchertseifer F; Morgenstern A; Seidl C
Eur J Nucl Med Mol Imaging; 2012 Apr; 39(4):602-12. PubMed ID: 22237842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]